We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva’s zero-hour attempt to prevent generic competition to its blockbuster multiple sclerosis drug Copaxone was halted May 14 when a federal judge threw out its lawsuit calling for ANDA applicants to meet additional requirements. Read More
The AstraZeneca board of directors on Monday rejected a sweetened, final merger offer from U.S. rival Pfizer, but at least one industry analyst expects wrangling will continue, especially if AZ shareholders step up and demand that the board returns to the negotiating table. Read More
Injectable drug maker Hospira has issued a voluntary recall of dobutamine injection, USP, after a customer complaint of discoloration in a single vial of the heart disease drug. Read More
Abbott Labs is poised to double its presence in generic pharmaceuticals in Latin America with a planned purchase of Chile-based generics manufacturer CFR Pharmaceuticals, the companies announced Friday. Read More
Novartis has gained an extra seven months of marketing exclusivity on its blockbuster leukemia drug Gleevec in a settlement with Sun Pharma that permits the Indian manufacturer to launch a generic version of the drug in the U.S. as early as Feb. 1, 2016, the firms said yesterday. Read More
Beleaguered Indian generics maker Wockhardt is recalling 109,744 bottles of the hypertension drug metoprolol due to problems with how the product dissolves in the body. Read More